Obsidian Therapeutics
1030 Massachusetts Avenue
Cambridge
Massachusetts
02138
United States
Tel: (781) 806-6245
Website: https://obsidiantx.com/
Email: info@obsidiantx.com
About Obsidian Therapeutics
Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients for the treatment of cancer and other diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.
Located in the heart of Cambridge, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.
41 articles with Obsidian Therapeutics
-
Obsidian Therapeutics Presents Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies
2/13/2018
Obsidian today announced the presentation of preclinical data on its technology platform and applications at the Keystone Symposium on Emerging Cellular Therapies, to be held February 11-15, 2018 in Keystone, Colorado.